Resveratrol: New avenues for a natural compound in neuroprotection

Current Pharmaceutical Design

Volumn 19, Issue 38, 2013, Pages 6726-6731

  Pallàs, Mercè ^a   Porquet, David ^a   Vicente, Alberto ^a   Sanfeliu, Coral ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INST D INVESTIGACIONS B   (Spain)

Author keywords

Aging; Autophagy; Inflammation; Neurodegeneration; Polyphenols; Resveratrol; Sirtuin 1

Indexed keywords

ANTIOXIDANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RESVERATROL; SIRTUIN 1; BIOLOGICAL PRODUCT; NEUROPROTECTIVE AGENT; SIRT1 PROTEIN, HUMAN; STILBENE DERIVATIVE;

AGING; ARTICLE; AUTOPHAGY; BIOGENESIS; CELL SURVIVAL; DEMOGRAPHY; DRUG EFFECT; HUMAN; MITOCHONDRION; NERVE CELL; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; DEGENERATIVE DISEASE; PHYSIOLOGY; REVIEW;

AGING; ANIMALS; ANTIOXIDANTS; AUTOPHAGY; BIOLOGICAL PRODUCTS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; SIRTUIN 1; STILBENES;

EID: 84896363752     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319380005     Document Type: Article

References (83)

1. [1] Vastano BC, Chen Y, Zhu N, Ho CT, Zhou Z, Rosen RT. Isolation and identification of stilbenes in two varieties of Polygonum cuspi-datum. J. Agri. Food Chem 2000; 48(2): 253-6.
2. [2] Albani D, Polito L, Signorini A, Forloni G. Neuroprotective prop- erties of resveratrol in different neurodegenerative disorders. Bio-Factors 2010; 36(5): 370-76.
3. [3] Vang O, Ahmad N, Baile CA, et al. What is new for an old mole- cule? systematic review and recommendations on the use of res-veratrol. PloS One 2011; 6(6): e19881.
4. [4] Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activa- tors of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425(6954): 191-6.
5. [5] Bass TM, Weinkove D, Houthoofd K, Gems D, Partridge L. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech Ageing Dev 2007; 128(10): 546-52.
6. [6] Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2006; 16(3): 296-300.
7. [7] Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444(7117): 337-42.
8. [8] Porquet D, Casadesús G, Bayod S, et al. Dietary resveratrol pre- vents Alzheimer's markers and increases life span in SAMP8.Age (Dordr) 2012
9. [9] Catalgol B, Batirel S, Taga Y, Ozer NK. Resveratrol: French para- dox revisited. Front. Pharmacology 2012; 3: 141.
10. [10] Nakata R, Takahashi S, Inoue H. Recent advances in the study on resveratrol. Biological Pharm Bulletin 2012; 35(3): 273-9.
11. [11] Agarwal B, Baur JA. Resveratrol and life extension. Ann New York Acad Sci 2011; 1215: 138-43.
12. [12] Knutson MD, Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutrition Rev 2008; 66(10): 591-6.
13. [13] Timmers S, Auwerx J, Schrauwen P. The journey of resveratrol from yeast to human. Aging (Albany NY) 2012; 4(3): 146-58.
14. [14] Amri A, Chaumeil JC, Sfar S, Charrueau S. Administration of resveratrol: what formulation solutions to bioavailability limitations? Journal of Controlled Release: Official J Controlled Release Soc 2012; 158(2): 182-93.
15. [15] Juan ME, González-Pons E, Planas JM. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in Rats. J Nutrition 2010; 140(3): 489-95.
16. [16] Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition: Biol Fate Chem 2004; 32(12): 1377-82.
17. [17] Mokni M, Ekahoui S, Limam F, Amri M, Aouani E. Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem Res 2007; 32(6): 981-7.
18. [18] Wang Q, Xu J, Rottinghaus GE, et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002; 958(2): 439-47.
19. [19] Mattson MP, Cheng A. Neurohormetic phytochemicals: Low-dose toxins that induce adaptive neuronal stress responses. Trends Neu-rosci 2006; 29(11): 632-9.
20. [20] Fauconneau B, Waffo-Teguo P, Huguet F, Barrier L, Decendit A, Merillon JM. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci 1997; 61(21): 2103-10
21. [21] Cristòfol R, Porquet D, Corpas R, et al. Neurons from senescence-accelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. J Pineal Res 2012; 52(3): 271-81.
22. [22] Sun AY, Draczynska-Lusiak B, Sun GY. Oxidized lipoproteins, beta amyloid peptides and Alzheimer's disease. Neurotox Res 2001; 3(2): 167-78.
23. [23] Liu GS, Zhang ZS, Yang B, He W. Resveratrol attenuates oxidative damage and ameliorates cognitive impairment in the brain of senescence-accelerated mice. Life Sci 2012; 91(17-18): 872-7.
24. [24] Huang TC, Lu KT, Wo YY, Wu YJ, Yang YL. Resveratrol protects rats from A|3-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One 2011; 6(12): e29102.
25. [25] Mudò G, Mäkelä J, Di Liberto V, et al. Transgenic expression and activation of PGC-1a protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci 2012; 69(7): 1153-65
26. [26] Ren J, Fan C, Chen N, Huang J, Yang Q. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem Res 2011; 36(12): 2352-62.
27. [27] Wu PF, Xie N, Zhang JJ, et al. Resveratrol preconditioning increases methionine sulfoxide reductases A expression and enhances resistance of human neuroblastoma cells to neurotoxins. J Nutr Biochem 2012; S0955-2863(12)00212-4.
28. [28] Palacios JA, Herranz D, De Bonis ML, Velasco S, Serrano M, Blasco MA. SIRT1 contributes to telomere maintenance and augments global homologous recombination. J Cell Biol 2010; 191(7): 1299-313.
29. [29] Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305(5682): 390-2.
30. [30] Rajamohan SB, Pillai VB, Gupta M, et al. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol 2009 29(15): 4116-29.
31. [31] Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA 2007; 104(31): 12861-6.
32. [32] Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell 2010; 38(6): 864-78.
33. [33] Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009; 9(4): 327-38.
34. [34] Hasegawa K, Yoshikawa K. Necdin regulates p53 acetylation via Sirtuin1 to modulate DNA damage response in cortical neurons. J Neurosci 2008; 28(35): 8772-84.
35. [35] Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 2007; 28(2): 277-90.
36. [36] Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 26; 303(5666) 2011-5.
37. [37] Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004 16; 23(12) 2369-80.
38. [38] Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in Rhesus monkeys. Science 2009 10; 325 (5937) 201-4.
39. [39] Mattison JA, Roth GS, Beasley TM, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012; 489(7415): 318-21.
40. [40] Barger JL, Kayo T, Vann JM, et al. A low dose of dietary resvera-trol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008; 4; 3(6): e2264.
41. [41] Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008; 8(2): 157-68.
42. [42] Smith JJ, Kenney RD, Gagne DJ, et al. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol 2009; 10: 30-1.
43. [43] Dai H, Kustigian L, Carney D, et al. SIRT1 Activation by Small Molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 2010; 285(43): 32695-703.
44. [44] Bordone L, Cohen D, Robinson A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Cell 2007; 6(6): 759-67.
45. [45] Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005; 280(17): 17187-95.
46. [46] Kaeberlein M, McDonagh T, Heltweg B, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 2005; 280(17): 17038-45.
47. [47] Beher D, Wu J, Cumine S, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009; 74(6): 619-24.
48. [48] Michán S, Li Y, Chou MM, et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci 2010; 30(29): 9695-707.
49. [49] Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007; 104(17): 7217-22.
50. [50] Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodi-esterases. Cell 2012 148(3): 421-33.
51. [51] Salminen A, Kaarniranta K. SIRT1: regulation of longevity via autophagy. Cell Signal 2009; 21(9): 1356-66.
52. [52] Rezzani R, Stacchiotti A, Rodella LF. Morphological and biochemical studies on aging and autophagy. Ageing Res Rev 2012; 11(1): 10-31.
53. [53] Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36(6): 585-95.
54. [54] Timmers S, Auwerx J, Schrauwen P. The journey of resveratrol from yeast to human. Aging (Albany NY) 2012; 4(3): 146-58.
55. [55] Lee IH, Cao L, Mostoslavsky R, et al.: A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagia. Proc. Natl. Acad. Sci. USA 2008; 105: 3374-9.
56. [56] Ghosh HS, McBurney M, Robbins PD. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One: 2010; 15; 5(2): e91995.
57. [57] Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 2008; 283: 27628-35.
58. [58] Armour SM, Baur JA, Hsieh SN, Land-Bracha A, Thomas SM, Sinclair DA. Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging (Albany NY) 2009; 1: 515-28.
59. [59] Ryter SW, Chen ZH, Kim HP, Choi AM. Autophagy in chronic obstructive pulmonary disease: homeostatic or pathogenic mechanism? Autophagy 2009; 5: 235-7.
60. [60] Chen ZH, Kim HP, Sciurba FC, et al. Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease PLoS One 2008; 3: e3316.
61. [61] Marchetti P, Masini M. Autophagy and the pancreatic beta-cell in human type 2 diabetes. Autophagy 2009; 5: 1055-6.
62. [62] Ost A, Svensson K, Ruishalme I, et al. Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes. Mol Med 2012; 16(7-8): 235-46.
63. [63] Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-79.
64. [64] May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998; 19: 80-8.
65. [65] Kumar A, Sharma SS. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun 2010; 394(2): 360-5.
66. [66] Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 2007; 30: 1-6
67. [67] Centeno-Baez C, Dallaire P, Marette A. Resveratrol inhibition of inducible nitric oxide synthase in skeletal muscle involves AMPK but not SIRT1. Am J Physiol Endocrinol Metab 2011; 301: E922-30.
68. [68] Chung EY, Kim BH, Hong JT, et al. Resveratrol down-regulates interferon-y-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J Nutr Biochem 2011; 22(10): 902-9.
69. [69] Annabi B, Lord-Dufour S, Vézina A, Béliveau R. Resveratrol targeting of carcinogen-induced brain endothelial cell inflammation biomarkers MMP-9 and COX-2 is Sirt1-independent. Drug Target Insights 2012; 6: 1-11.
70. [70] Gentilli M, Mazoit JX, Bouaziz H, et al. Resveratrol decreases hyperalgesia induced by carrageenan in the rat hind paw. Life Sci 2001; 68(11): 1317-21.
71. [71] Ghanim H, Sia CL, Abuaysheh S, et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Poly-gonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010; 95: E1-E8.
72. [72] Rosa FT, Zulet MÁ, Marchini JS, Martínez JA. Bioactive compounds with effects on inflammation markers in humans. Int J Food Sci Nutr 2012; 63(6): 749-65.
73. [73] Sharma M, Gupta YK. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 2002; 71(21): 2489-98.
74. [74] Kumar A, Naidu PS, Seghal N, Padi SS. Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology 2007; 79(1): 17-26.
75. [75] Chang J, Rimando A, Pallas M, et al. Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol Aging 2012; 33(9): 2062-7.
76. [76] Lu X, Ma L, Ruan L, et al. Resveratrol differentially modulates inflammatory responses of microglia and astrocytes J Neuroin-flammation 2010; 7: 46.
77. [77] Son YH, Jeong YT, Lee KA, et al. Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. J Cardiovasc Pharmacol 2008; 51(1): 71-7.
78. [78] Kim J, Lee HJ, Lee KW. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J Neurochem 2010; 112(6): 1415-30.
79. [79] Pallauf K, Rimbach G. Autophagy, polyphenols and healthy ageing. Ageing Res Rev 2012; 12(1): 237-52.
80. [80] Gräff J, Rei D, Guan JS, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012; 483(7388): 222-6
81. [81] Ford D, Ions LJ, Alatawi F, Wakeling LA. The potential role of epigenetic responses to diet in ageing. Proc Nutr Soc 2011; 70(3): 374-84.
82. [82] Wakeling LA, Ions LJ, Ford D. Could Sirt1-mediated epigenetic effects contribute to the longevity response to dietary restriction and be mimicked by other dietary interventions? Age (Dordr) 2009; 31(4): 327-34.
83. [83] Alarcón JM, Malleret G, Touzani K, et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 2004; 42(6): 947-59.